We present a case report of a 66-year old woman with breast cancer treated with trastuzumab, a monoclonal antibody against the HER2 receptor. Treatment with trastuzumab was complicated by the development of Guillain-Barre syndrome, well documented by EMG examination, cerebrospinal fluid analysis and clinical course with a relatively good outcome after plasmapheresis and intravenous immunoglobulins.